Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 12/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 6/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38651021 | 1.00 | L3MBTL1 (0.44) | L3MBTL1SLC5A2DRD4HTR2ASLC6A4 | |
| SCHEMBL16608734 | 0.93 | PKM (0.46) | L3MBTL1SLC5A2HTR2ASLC6A4KCNH2 | |
| SCHEMBL499821 | 0.90 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL3684101 | 0.87 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL38150 | 0.86 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL29386304 | 0.86 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL10211827 | 0.86 | SLC5A2 (0.44) | L3MBTL1SLC5A2SLC5A1 | |
| SCHEMBL14938792 | 0.85 | SLC5A2 (0.52) | SLC5A2SLC5A1 | |
| SCHEMBL31086477 | 0.84 | SLC5A2 (0.57) | SLC5A2SLC5A1CCR5 | |
| SCHEMBL499441 | 0.84 | SLC5A2 (0.57) | SLC5A2SLC5A1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024060271-A1 | CHARACTERISTIC IMPURITY IN EMPAGLIFLOZIN BULK DRUG OR PREPARATION AND USE THEREOF | 浙江宏元药业股份有限公司 | 2024-03-28 | — | — | WO | disclosed |